TP53 and prostate carcinoma: They used human cervical carcinoma HeLa, human prostate carcinoma DU145 and human colorectal carcinoma HCT116 p53+/+ and p53−/− cells treated with and without cisplatin, which are known to induce apoptosis by producing reactive oxygen species.